Analysts Set Expectations for Sutro Biopharma Q2 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO) – HC Wainwright issued their Q2 2025 earnings estimates for shares of Sutro Biopharma in a report released on Monday, November 18th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.87) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q4 2025 earnings at ($0.96) EPS.

Other analysts have also recently issued reports about the company. Truist Financial reduced their price target on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 16th. JMP Securities reissued a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Monday, September 16th. Finally, Piper Sandler restated an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a research note on Friday, October 11th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $12.14.

Sutro Biopharma Stock Down 1.8 %

Shares of NASDAQ:STRO opened at $2.70 on Tuesday. Sutro Biopharma has a 12-month low of $2.13 and a 12-month high of $6.13. The business has a 50 day moving average of $3.68 and a 200-day moving average of $3.82. The stock has a market cap of $222.64 million, a PE ratio of -1.68 and a beta of 1.17.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. lifted its position in Sutro Biopharma by 1,606.1% during the second quarter. Point72 Asset Management L.P. now owns 4,447,634 shares of the company’s stock worth $13,032,000 after purchasing an additional 4,186,938 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Sutro Biopharma by 4.6% during the 1st quarter. Vanguard Group Inc. now owns 3,022,790 shares of the company’s stock worth $17,079,000 after acquiring an additional 132,790 shares during the period. Geode Capital Management LLC boosted its position in shares of Sutro Biopharma by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock worth $6,426,000 after acquiring an additional 132,015 shares in the last quarter. State Street Corp boosted its position in shares of Sutro Biopharma by 5.2% during the 3rd quarter. State Street Corp now owns 1,647,162 shares of the company’s stock worth $5,699,000 after acquiring an additional 81,855 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Sutro Biopharma by 30.8% in the second quarter. Acadian Asset Management LLC now owns 1,574,958 shares of the company’s stock valued at $4,613,000 after acquiring an additional 370,705 shares during the last quarter. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.